Activity and safety of avelumab in high-grade neuroendocrine tumors and poorly differentiated neuroendocrine carcinomas progressive after chemotherapy (AveNEC trial)

CONCLUSIONS: In patients with progressive high-grade NEN G3, avelumab was well tolerated and provided disease control with significant clinical benefit in 15% of heavily pretreated …